Scholarlink

Introduction <p>Long-term real-world data on vedolizumab outcomes remain limited: the LONG-LIVE study evaluates 5-year effectiveness and safety in a large Italian cohort.</p> Methods <p>This is a long-term extension of the multicenter LIVE study involving patients with Crohn’s disease (CD) and ulcerative colitis (UC). The primary outcome was the cumulative probability of major adverse clinical outcomes (the composite of IBD-related surgeries, non-surgical hospitalizations, and serious adverse events). Secondary outcomes included cumulative incidences of IBD-related surgery and non-surgical hospitalization, vedolizumab persistence, rates of death, cancer and adverse events of special interest (AESIs), and longitudinal response group transitions; outcomes in elderly patients (≥ 65&#xa0;years) were compared to non-elderly using inverse probability weighting (IPW).</p> Results <p>Overall, 782 patients were included (50.4% CD; 49.6% UC; 76.3% anti-tumor necrosis factor (TNF)-experienced; 4324.1 patient-years of follow-up). The 5-year probability of major adverse clinical outcomes was 29.4% (no difference between CD and UC). In CD, penetrating behavior (aHR 1.77) predicted higher risk of the primary endpoint, while colonic location was protective (aHR 0.51). In UC, the primary endpoint was predicted by elderly age (aHR 1.99) and comorbidity burden (aHR 1.27). Five-year cumulative incidences were 23.4% for surgery and 14.3% for non-surgical hospitalization. Patients with CD had higher hospitalization risk than patients with UC (sHR 1.80). Mortality, neoplasm diagnosis, and AESIs occurred at rates of 3.93, 3.93, and 6.27 per 1000 patient-years. Five-year drug persistence was 38.7%. Achieving deep remission within 24&#xa0;months mediated the relationship between initial clinical response and sustained deep remission at last follow-up. After IPW, elderly patients had a higher risk of major adverse clinical outcomes and non-surgical hospitalization; AESI and cancer rates did not differ.</p> Conclusion <p>Approximately one in three patients experienced a major adverse clinical outcome over 5&#xa0;years, driven primarily by disease-related complications rather than adverse events, with a consistent safety profile across age groups.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Giuseppe Privitera,
  • Flavia Palumbo,
  • Fabio Salvatore Macaluso,
  • Lucrezia Laterza,
  • Veronica Pardi,
  • Anna Viola,
  • Daniele Noviello,
  • Brigida Barberio,
  • Chiara Ricci,
  • Paola Balestrieri,
  • Maria Cappello,
  • Giovanni Maconi,
  • Renato Sablich,
  • Angela Variola,
  • Raffaele Bennato,
  • Luca Pastorelli,
  • Laurino Grossi,
  • Davide Giuseppe Ribaldone,
  • Andrea Buda,
  • Fabrizio Bossa,
  • Antonio Di Sario,
  • Angelo Viscido,
  • Benedetto Neri,
  • Giammarco Mocci,
  • Cristiano Pagnini,
  • Maria Beatrice Principi,
  • Marina Coletta,
  • Carlo Petruzzellis,
  • Silvia Mazzuoli,
  • Stefano Festa,
  • Agnese Mirarnda,
  • Cristina Bezzio,
  • Libera Fanigliulo,
  • Giulia Rocco,
  • Elisabetta Dal Pont,
  • Rocco Spagnuolo,
  • Edoardo Vincenzo Savarino,
  • Flavio Andrea Caprioli,
  • Walter Fries,
  • Linda Ceccarelli,
  • Franco Scaldaferri,
  • Ambrogio Orlando,
  • Anna Testa,
  • Daniela Pugliese,
  • Alessandro Armuzzi

摘要

Introduction

Long-term real-world data on vedolizumab outcomes remain limited: the LONG-LIVE study evaluates 5-year effectiveness and safety in a large Italian cohort.

Methods

This is a long-term extension of the multicenter LIVE study involving patients with Crohn’s disease (CD) and ulcerative colitis (UC). The primary outcome was the cumulative probability of major adverse clinical outcomes (the composite of IBD-related surgeries, non-surgical hospitalizations, and serious adverse events). Secondary outcomes included cumulative incidences of IBD-related surgery and non-surgical hospitalization, vedolizumab persistence, rates of death, cancer and adverse events of special interest (AESIs), and longitudinal response group transitions; outcomes in elderly patients (≥ 65 years) were compared to non-elderly using inverse probability weighting (IPW).

Results

Overall, 782 patients were included (50.4% CD; 49.6% UC; 76.3% anti-tumor necrosis factor (TNF)-experienced; 4324.1 patient-years of follow-up). The 5-year probability of major adverse clinical outcomes was 29.4% (no difference between CD and UC). In CD, penetrating behavior (aHR 1.77) predicted higher risk of the primary endpoint, while colonic location was protective (aHR 0.51). In UC, the primary endpoint was predicted by elderly age (aHR 1.99) and comorbidity burden (aHR 1.27). Five-year cumulative incidences were 23.4% for surgery and 14.3% for non-surgical hospitalization. Patients with CD had higher hospitalization risk than patients with UC (sHR 1.80). Mortality, neoplasm diagnosis, and AESIs occurred at rates of 3.93, 3.93, and 6.27 per 1000 patient-years. Five-year drug persistence was 38.7%. Achieving deep remission within 24 months mediated the relationship between initial clinical response and sustained deep remission at last follow-up. After IPW, elderly patients had a higher risk of major adverse clinical outcomes and non-surgical hospitalization; AESI and cancer rates did not differ.

Conclusion

Approximately one in three patients experienced a major adverse clinical outcome over 5 years, driven primarily by disease-related complications rather than adverse events, with a consistent safety profile across age groups.

Graphical Abstract